Skip to main content
. 2017 Oct 26;16:430. doi: 10.1186/s12936-017-2074-7

Fig. 5.

Fig. 5

Cumulative failure estimates for drugs with different terminal elimination half-lives. The solid line represents K–M cumulative failure probabilities and the dotted line represents the drug levels with hypothetical units presented on the right y-axis. Drug B (blue) has a longer elimination half-life and the recrudescent failures are more patent after day 21 compared to drug A (red) with a short half-life and recrudescences being observed after day 7